Disease biology and the case for multi-target intervention in ADPKD

Autosomal dominant polycystic kidney disease is the most common hereditary cause of renal failure, affecting approximately 1 in 500–1,000 live births and accounting for roughly 5% of end-stage renal disease cases in the United States. The disease is caused by loss-of-function mutations in PKD1 (encoding polycystin-1, PC-1) or PKD2 (encoding polycystin-2, PC-2), with PKD1 mutations responsible for approximately 85% of cases. PC-1 and PC-2 co-localise on primary cilia of renal tubular cells and regulate calcium signalling; their disruption triggers aberrant intracellular calcium influx, cAMP accumulation, and mTOR pathway hyperactivation — collectively driving epithelial cell proliferation, fluid secretion, and cyst expansion.

The signalling network disrupted in ADPKD is not a single linear pathway — it is a convergent hub. Elevated cAMP drives cyst growth through the vasopressin V2 receptor (AVPR2) axis; mTOR hyperactivation promotes epithelial proliferation; miR-17 family members suppress polycystin mRNA stability; and CFTR-mediated chloride secretion fills expanding cysts with fluid. This multi-node architecture explains why the patent landscape, as synthesised from patent and academic literature evidence, spans at least seven distinct therapeutic modalities — and why combination strategies are increasingly prominent across recent filings.

Aberrant fatty acid metabolism in cystic kidneys has also been identified by researchers at the University of Pennsylvania as an emerging common mechanism linking PKD to broader chronic kidney disease pathophysiology, pointing to metabolic reprogramming as an additional therapeutic axis. According to NIH-funded research, the interplay between metabolic and proliferative signalling in cystic epithelial cells remains an active area of investigation.

Vasopressin V2 receptor antagonism: tolvaptan, ticagrelor, and combination strategies

Tolvaptan — a vasopressin V2 receptor antagonist — is the only FDA-approved agent for ADPKD, and its mechanism directly addresses the cAMP axis. High arginine vasopressin (AVP) levels elevate adenylyl cyclase activity in renal tubular cells, increasing intracellular cAMP and driving cyst growth. Tolvaptan inhibits this adenylyl cyclase activity to reduce cAMP levels, thereby attenuating cyst proliferation and fluid secretion, as described in academic literature from the University Medical Center Groningen (2019). However, tolvaptan’s utility is constrained by aquaretic side effects and its efficacy is limited to renal compartments.

The drug’s hepatotoxicity liability — including black-box liver failure warnings and an FDA REMS program requirement — has become the primary commercial pressure point in the vasopressin pathway space. A 2024 patent from Esperion Therapeutics, Inc. (filed in Japan) describes a fixed-dose combination of bempedoic acid and tolvaptan for ADPKD, explicitly acknowledging tolvaptan’s hepatotoxicity risk as the impetus for combination strategies intended to reduce tolvaptan exposure while preserving efficacy. The Torres et al. pivotal trial published in the New England Journal of Medicine in 2012 is cited in the Esperion filing as the foundational clinical evidence base for tolvaptan.

“Tolvaptan’s hepatotoxicity liability — black-box liver failure warnings and an FDA REMS requirement — has become the primary commercial pressure point driving combination strategies and upstream AVP-targeting alternatives.”

Two active US patents from the United States Department of Veterans Affairs (2020 and 2022) disclose a distinct upstream approach: administering ticagrelor, a P2Y12 antagonist, to decrease endogenous AVP production, thereby reducing cAMP signalling in ADPKD. Rather than blocking the V2 receptor directly, this strategy reduces the ligand driving it. The approach has been validated at the preclinical level. Academic literature from the University Medical Center Groningen (2019) also documents somatostatin analogues as a further means of suppressing AVPR2 pathway activity in ADPKD patients, representing a clinical-stage translational signal for somatostatin/AVP pathway co-modulation.

mTOR pathway inhibition and CFTR modulation via Hsp90: converging on cyst proliferation and fluid secretion

The mTOR pathway is the most pharmacologically targeted downstream signalling cascade in the ADPKD patent landscape analysed here. Disrupted calcium signalling downstream of PKD1/PKD2 mutations leads to mTOR hyperactivation, and mTOR inhibitors including rapamycin, everolimus, and sirolimus appear in at least three distinct patent estates as treatment agents or combination partners. Biomarkers pS6, pAkt, P-mTOR, and P-S6K are repeatedly cited as validated readouts of pathway activity in ADPKD patient tissue and animal models across Genzyme, University of Kansas, and Monash University patent families.

The University of Kansas (US and WO patents, 2011) provides the most mechanistically detailed small-molecule approach in the dataset. Novobiocin analogues of the coumarin-3-carboxamide class are claimed to reduce levels of mTOR pathway phosphoproteins P-mTOR, P-Akt, and P-S6K in ADPKD models by degrading Hsp90 client proteins. The same patent explicitly co-targets CFTR, ErbB2, c-Raf, and Cdk4 as Hsp90 client proteins — linking mTOR pathway suppression and CFTR-mediated cyst fluid accumulation in a single chemical scaffold. This polypharmacological design addresses both the proliferative and secretory drivers of cyst expansion simultaneously.

A Board of Regents of the University of California patent (CN, 2014) claims use of mTOR-targeting kinase inhibitors as direct therapeutic interventions in polycystic disease, grounding the rationale in disrupted calcium signalling. Revolution Medicines, Inc. (SG, 2019) filed patents on rapamycin analogue mTOR inhibitors, and Janssen Pharmaceutical (CN, 2023) filed for rapamycin analogues with explicit utility in mTORC1-related renal fibrosis. Critically, the University of Kansas novobiocin analogue patents are now inactive — a status that may indicate freedom-to-operate for this scaffold class and potentially open the chemical space for follow-on development, as noted by WIPO patent expiry frameworks.

Monash University (WO, AU, US; 2021–2022) patents extend the PI3K/Akt axis further, describing inhibition of AKT and/or Aurora kinase A (AURKA) as an approach to minimising renal cystogenesis. Dual AKT pT308 and AURKA high-expression collecting duct cells are identified as key cystogenic cell populations in PKD mouse models. Genetic deletion of AURKA in Pkd1 knockout mice reduces AKT pT308-high cell populations and cyst burden, supporting a therapeutic rationale for dual AURKA/AKT inhibition. Alisertib, an AURKA inhibitor, is discussed experimentally in these filings.

Anti-miR-17 oligonucleotides and polycystin-restoring antisense strategies: the RNA frontier in PKD

The most numerically dense modality cluster in the patent dataset involves modified oligonucleotides targeting the microRNA miR-17 family. miR-17 family members of the miR-17~92 cluster are upregulated in PKD mouse models; their genetic deletion reduces cyst growth, improves renal function, and prolongs survival, as established in PNAS 2013 data cited in University of Texas System filings. miR-17 suppresses PKD1 and PKD2 mRNA stability, making its inhibition a mechanism for restoring polycystin expression — the same molecular axis targeted by polycystin-restoring ASOs through distinct mechanisms.

Regulus Therapeutics, Inc. (active filer across CN, CL, SA, TW; 2019–2025) and the Board of Regents of the University of Texas System (US, AU, IN, SG, WO; 2018–2020) hold overlapping patent estates covering anti-miR-17 modified oligonucleotides. The Regulus CN patents (2024–2025) disclose compounds designated RG-NG-1015, RG-NG-1001, RGLS4326, and RG-NG-1017, with efficacy data from a Pkd1-F/RC mouse model. Maximum tolerated dose studies and AMPA receptor safety differentiation between congeners are disclosed — activities consistent with an IND-enabling package as evaluated against standards from FDA guidance for oligonucleotide therapeutics.

A parallel and mechanistically complementary wave of filings targets PC-1 dosage restoration directly. Approximately 85% of ADPKD is caused by PKD1 mutations, and the only previously known method to increase PC-1 expression was microRNA-17 inhibition — contextualising anti-miR-17 and PKD1-stabilising ASOs as convergent strategies on the same molecular axis. Four distinct institutional approaches have emerged in the 2022–2026 filing window:

• Mayo Foundation for Medical Education and Research (WO, CA, AU; 2022–2024): nucleic acid-based strategies to increase PC-1 and/or PC-2 polypeptide levels in ADPKD.
• Board of Regents, University of Texas System (AU, 2025): a “PKD-stabilising oligonucleotide” targeting and inhibiting regulatory elements in the 3′ UTR of PKD1 mRNA and/or PKD2 mRNA, de-repressing their translation.
• Yale University (CN, JP; 2025): compounds that suppress translation of upstream open reading frames (uORFs) 1–4 in the PKD1 gene, increasing PC-1 functional dosage in ADPKD and polycystic liver disease.
• PYC Therapeutics (CN, 2026 priority date): antisense oligonucleotides designed to increase PKD1 mRNA and polycystin-1 protein levels.

These approaches are mechanistically complementary — targeting 5′-UTR uORF suppression versus 3′-UTR de-repression versus mRNA stabilisation — and signals suggest growing consensus that PC-1 restoration represents a disease-modifying strategy orthogonal to symptom management. The convergence of multiple academic and biotech institutions on this axis within a three-year window is a strong signal of scientific momentum, consistent with patterns identified in Nature reviews of oligonucleotide therapeutic development timelines.

IP landscape, assignee dynamics, and strategic white space for ADPKD drug developers

The ADPKD patent landscape is characterised by dense IP concentration in oligonucleotide modalities and relatively open territory in small-molecule mTOR inhibition. The anti-miR-17 IP space is densely occupied by Regulus Therapeutics and the University of Texas System across multiple jurisdictions, with compounds progressing through IND-enabling studies. Drug developers entering this space face significant freedom-to-operate constraints; differentiation may require novel chemical modifications — sugar moieties, backbone chemistry — or distinct delivery modalities beyond those already disclosed, consistent with guidance from EMA on oligonucleotide therapeutic differentiation.

PC-1/PC-2 restoration represents an underexplored but rapidly crowding therapeutic axis. Yale University, Mayo Foundation, University of Texas System, and PYC Therapeutics have each filed distinct strategies to increase polycystin expression in the 2022–2026 window. The convergence of uORF suppression, 3′-UTR de-repression, and nucleic acid delivery improvements into overlapping IP families suggests this will become a competitive and potentially litigated space within three to five years.

“mTOR inhibitor IP is mostly lapsed or available: the University of Kansas novobiocin analogue patents are inactive, opening significant freedom-to-operate for mTOR inhibitor repositioning in ADPKD.”

Genzyme Corporation (now part of Sanofi) is the most volumetrically represented assignee in the dataset, with more than ten patent families across US, EP, AU, SG, JP, WO, MX, CO, and KR jurisdictions covering PKD biomarker diagnostics. Genzyme’s activity is exclusively patent-driven in this dataset, suggesting a commercial IP strategy around companion diagnostics for PKD therapeutic monitoring. Companies developing mTOR inhibitors or PI3K/Akt-targeting agents for ADPKD who wish to use pS6, pAkt, or pERK as companion diagnostics may need to navigate Genzyme’s IP portfolio or develop independent biomarker panels.

The US Department of Veterans Affairs holds active and inactive US patents (2020, 2022) on ticagrelor as an AVP-reducing agent for ADPKD — a government assignee situation that may offer potential for royalty-free licensing or public domain transfer, representing a navigable white space for developers seeking upstream AVP-pathway modulators without the core tolvaptan V2R mechanism.

Combination strategies are the clearest near-term development signal. The University of Texas System patents explicitly enumerate tolvaptan, everolimus, rapamycin, sirolimus, bosutinib, somatostatin analogues, and spironolactone as combination partners for anti-miR-17 oligonucleotides — the most extensively enumerated combination framework in the dataset. Esperion Therapeutics’ bempedoic acid + tolvaptan fixed-dose combination patent (JP, 2024) signals a dose-reduction/safety optimisation rationale. The University of Kansas novobiocin analogue approach, now with inactive patents, simultaneously targeted P-mTOR/P-Akt/P-S6K and CFTR/ErbB2/c-Raf/Cdk4 via Hsp90 inhibition — a polypharmacological scaffold whose chemical space may now be open for follow-on development.

For IP strategists and drug developers, the PatSnap IP intelligence platform and PatSnap drug discovery tools provide the jurisdictional coverage and assignee analytics needed to map freedom-to-operate across the ADPKD landscape in real time.